The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed

OpenAI is the latest tech giant to move into biopharma, announcing a life sciences-focused AI offering on Thursday. The San Francisco-based company announced GPT-Rosalind, effectively

A new report trying to settle a decades-old debate about Alzheimer’s disease has reached a dramatic conclusion: Antibody drugs that target sticky amyloid beta proteins

Roche said it will run a new Phase 3 trial for the controversial Duchenne muscular dystrophy gene therapy Elevidys in another attempt to win approval

💰 MeiraGTx buys back eye gene therapy from J&J for just $25M: The gene therapy, known as bota-vec, failed a Phase 3 study for X-linked